Emergent BioSolutions (EBS) EBT Margin Growth (3y) (2014 - 2026)

Emergent BioSolutions (EBS) EBT Margin Growth (3y) (2014 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin Growth (3y) (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 1,840.00
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn -134.00
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -5,626.00
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -1,686.00
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn -1,570.00
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 5,487.00
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -225.00
10 Emergent BioSolutions 389.77 Mn 228.27 Mn 84.10 Mn 10,633.00

Historic Data

Download Data
DateValue
Mar 31, 2026 10,633.00
Dec 31, 2025 -1,550.00
Sep 30, 2025 5,294.00
Jun 30, 2025 2,221.00
Mar 31, 2025 4,297.00
Dec 31, 2024 -4,915.00
Sep 30, 2024 6,436.00
Jun 30, 2024 -54,151.00
Mar 31, 2024 -1,857.00
Dec 31, 2023 -6,387.00
Sep 30, 2023 -11,258.00
Jun 30, 2023 -10,463.00
Mar 31, 2023 -8,668.00
Dec 31, 2022 -3,843.00
Sep 30, 2022 -4,690.00
Jun 30, 2022 -2,792.00
Mar 31, 2022 1,859.00
Dec 31, 2021 3,368.00
Sep 30, 2021 -2,827.00
Jun 30, 2021 -2,797.00